Impedance Spectroscopy in Detection of Obstetric Anal Sphincter Injuries
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03769792 |
Recruitment Status :
Completed
First Posted : December 10, 2018
Last Update Posted : March 4, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The main purpose of the study is to evaluate the effectiveness and safety of the impedance spectroscopy device prototype in detection of anal sphincter injuries in women in the early postpartum period. The study is prospective. The study group comprises 24 patients; included in it 6-8 weeks after natural delivery. The planned participation of each patient in the study is up to 4 weeks and three visits will take place at that time.
After obtaining written consent, at the screening visit (V0) each patient will undergo a physical examination, blood samples for laboratory tests and stool samples for calprotectin concentration assessment will be collected.
On the second visit (V1), after the final verification of inclusion/exclusion criteria, impedance spectroscopy using tested device will be performed in each patient, the electrical impedance of pelvic floor muscles will be measured and the degree of anal sphincter damage will be evaluated. Full gynecological and proctological examination (including a gynecological speculum, two-handed examination, rectal examination and anoscopy) will be carried out.
On the third visit (V2), two reference diagnostic tests (with evidenced effectiveness and safety), transanal ultrasonography and anorectal manometry, will be conducted. The collected data will be used to select the optimal therapeutic method for each participant individually.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obstetric Anal Sphincter Injury Delivery, Obstetric | Diagnostic Test: Blood and faeces tests Device: Impedance spectroscopy test Diagnostic Test: Full gynecological and proctological examination Diagnostic Test: Transanal ultrasonography Diagnostic Test: Anorectal manometry | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Evaluation of the Effectiveness and Safety of Impedance Spectroscopy Device in Detecting Sphincter Injuries in Women After Natural Delivery |
Actual Study Start Date : | February 4, 2019 |
Actual Primary Completion Date : | October 30, 2019 |
Actual Study Completion Date : | December 23, 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: Impedance spectroscopy
24 women will be included in the study and divided into two subgroups. 12 of them (first subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 1 or 2 in OASIS classification. Remaining 12 (second subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 3 or 4 in OASIS classification. The planned interventions are:
|
Diagnostic Test: Blood and faeces tests
During V0 - Laboratory tests, particularly for calprotectin concentration assessment Device: Impedance spectroscopy test During V1 - the electrical impedance of pelvic floor muscles will be measured Diagnostic Test: Full gynecological and proctological examination During V1 - Examination with a gynecological speculum, Two-handed examination, Rectal examination and Anoscopy Diagnostic Test: Transanal ultrasonography During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results. Diagnostic Test: Anorectal manometry During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results. |
- Anal sphincters injury [ Time Frame: 8 weeks ]
Assessed by subsequent measures:
- Sphincter continuity in physical examination,
- Sphincter tension in physical examination,
- OASIS classification of perineal tears in transanal ultrasonography
- Starck scale for classification of anal sphincter injuries in transanal ultrasound (0-16 scale, no defect - 0; maximum - 16, means severe damage of both sphincters on a considerable length and circumference)
- Norderval scale for classification of anal sphincter injuries in transanal ultrasound (0-7 scale, no defect - 0, 7 is the maximal damage of both anal sphincters)
- anorectal manometry assessment to measure anal sphincters function
All measurements are used to estimate the presence, extent and severity of anal sphincter injury.
The main aim of the study is to establish whether the extension and severity of obstetric anal sphincter injury can be precisely assessed with parameters calculated from pelvic floor muscles using impedance spectroscopy.
- Adverse events [ Time Frame: 8 weeks ]Evaluation of the frequency and intensity of adverse events associated with the use of the new diagnostic method.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 49 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- after natural delivery and post-partum period (6-8 weeks after delivery)
- physiological pregnancy
- observed a perianal tear of grade 1-4 in the OASIS classification
- signed informed consent
Exclusion Criteria:
- presence of acute diseases during treatment
- presence of chronic diseases untreated or insufficiently treated (e.g. poorly controlled hypertension),
- presence of diseases, with symptoms of fecal incontinence,
- previous proctological operations,
- the presence of inflammatory bowel diseases in the stage of exacerbation,
- treatment in the last year due to severe, progressive, uncontrolled cardiac, pulmonary, nephrological, infectious or psychiatric disease, which course could affect the patient's risk due to participation in study,
- significant deviations from the norm in a physical examination during V0 visit or laboratory tests taken during the same visit,
- significant disease symptoms so far undiagnosed and reported during the V0 visit
- presence or suspected malignant disease or previous oncological treatment during the last 5 years,
- presence of a cardiac stimulator or cardioverter-defibrillator,
- severe surgery or severe trauma in the last year.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03769792
Poland | |
Centrum Medyczne Byc Kobieta s.c. | |
Łódź, Lodzkie, Poland, 95-070 |
Principal Investigator: | Grzegorz Surkont, MD, PhD | Centrum Medyczne Byc Kobieta s.c. |
Responsible Party: | OASIS Diagnostics S.A. |
ClinicalTrials.gov Identifier: | NCT03769792 |
Other Study ID Numbers: |
1/1/2018 (Sep 8) |
First Posted: | December 10, 2018 Key Record Dates |
Last Update Posted: | March 4, 2020 |
Last Verified: | March 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Obstetrical anal sphincter injury Impedance spectroscopy |
Wounds and Injuries |